New Brunswick, New Jersey, United States, November 19, 2026
Johnson & Johnson (J&J) has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), seeking approval of CAPLYTA® (lumateperone) for the treatment of manic or mixed episodes associated with bipolar I disorder in adults. The regulatory submission is supported by positive findings from two pivotal Phase 3 clinical trials, which demonstrated significant reductions in manic symptoms compared with placebo. According to the company, improvements were observed as early as Day 3 and were sustained through the three-week treatment period. If approved, bipolar mania would become the fifth adult indication for CAPLYTA, expanding its potential role in managing serious psychiatric conditions. The application follows the completion of two randomised, double-blind, placebo-controlled studies, designated Study 451 and Study 452. Both trials met their primary and key secondary endpoints, demonstrating improvements in manic symptoms and overall illness severity. The submission represents another development in J&J’s neuroscience portfolio and its efforts to address different phases of bipolar I disorder through pharmacological treatment.
Two Phase 3 Studies Support FDA Submission
The sNDA is based on Study 451 and Study 452, which evaluated once-daily CAPLYTA 42 mg against placebo in adults experiencing manic episodes, with or without mixed features, associated with bipolar I disorder. Each study used a three-week treatment period and assessed changes in symptoms using established clinical rating scales. The primary endpoint was the change from baseline in the Young Mania Rating Scale (YMRS) total score at Week 3, while the key secondary endpoint measured changes in the Clinical Global Impression–Severity (CGI-S) score. Both studies achieved their primary and key secondary endpoints, indicating statistically significant improvements in manic symptoms and overall illness severity compared with placebo. In Study 452, CAPLYTA produced a 3.7-point greater reduction in YMRS total score than placebo at Week 3, with an effect size of -0.43 and a p-value below 0.0001. Improvements were observed as early as Day 3 and continued through Week 3. Furthermore, 43.9% of participants receiving CAPLYTA achieved at least a 50% improvement in YMRS scores, compared with 23.7% of participants receiving placebo. The CGI-S results also favoured CAPLYTA, with a statistically significant improvement at Week 3. These findings provide additional clinical evidence supporting the regulatory application for the investigational use in bipolar mania.
CAPLYTA Targets a Broader Range of Bipolar Symptoms
CAPLYTA is an oral, once-daily atypical antipsychotic containing the active ingredient lumateperone. It is already FDA-approved for several adult psychiatric indications, including depressive episodes associated with bipolar I or bipolar II disorder, either as monotherapy or as adjunctive treatment with lithium or valproate. It is also approved for schizophrenia and as adjunctive therapy with antidepressants for major depressive disorder. The proposed bipolar mania indication would extend the medicine’s use into the treatment of acute manic or mixed episodes associated with bipolar I disorder. Bipolar I disorder is characterised by episodes of mania that may occur alongside depressive episodes. Mania can involve elevated or irritable mood, increased energy, reduced need for sleep, racing thoughts, distractibility and risk-taking behaviour. These symptoms can significantly affect personal relationships, occupational functioning and overall wellbeing, and severe episodes may require hospitalisation. The ability to manage manic symptoms is therefore an important component of treatment. Although the precise mechanism of action of lumateperone is not fully established, its pharmacological activity includes effects on central serotonin 5-HT2A and dopamine D2 receptors. The company is seeking to build on CAPLYTA’s existing clinical and safety experience through the proposed expanded indication.
Regulatory Milestone and Safety Considerations
The two pivotal studies reported that CAPLYTA was generally well tolerated, with low discontinuation rates and a safety profile consistent with previous clinical studies. In Study 452, commonly reported treatment-related adverse events occurring more frequently with CAPLYTA included dizziness, dry mouth and somnolence or sedation. As with other antipsychotic medicines, treatment decisions require consideration of individual patient circumstances, potential adverse reactions and appropriate clinical monitoring. The submission does not mean that the FDA has approved CAPLYTA for bipolar mania. The medicine remains approved for its existing indications, while the proposed use for manic or mixed episodes associated with bipolar I disorder is awaiting regulatory review. If the FDA grants approval, CAPLYTA could become an additional treatment option for adults experiencing acute mania, alongside its established uses in bipolar depression, schizophrenia and major depressive disorder. The application also highlights the importance of clinical evidence generated through controlled Phase 3 studies in supporting expanded indications for established medicines. The FDA’s final regulatory decision will determine whether CAPLYTA can be marketed for bipolar mania in the United States.
Source: Johnson & Johnson press release



